Following a request from the European Commission, the European Food Safety Authority was asked to deliver a scientific opinion on the proposal for reducing the withdrawal period from three days to one day and the setting of a final maximum residue limit (MRL) for the product Coxidin ® for chickens and turkeys for fattening.
BACKGROUND Regulation (EC) No 1831/2003 2 establishes the rules governing the Community authorisation of additives for use in animal nutrition. In particular, Article 13(3) of that Regulation lays down that if the holder of an authorisation proposes changing the terms of the authorisation by submitting an application to the Commission, accompanied by the relevant data supporting the request for the change, the Authority shall transmit its opinion on the proposal to the Commission and the Member States.
The European Commission received a request from the company Huvepharma NV 3 to modify the withdrawal period from three days to one day and to set the final MRL for the product Coxidin ® (monensin sodium), to be used as a feed additive for chickens and turkeys for fattening (category: coccidiostats) under the conditions mentioned in Table 1 .
The product Coxidin ® is a preparation of monensin sodium which has been initially authorised at Community level under Regulation (EC) No 109/2007 4 and than under Regulation (EC) No 156/2008 5 for use in chickens and turkeys for fattening, until 6 February 2017.
According to Article 7(1) of Regulation (EC) No 1831/2003, the Commission forwarded the application to the European Food Safety Authority (EFSA) as an application under Article 13(3) (modification of the authorisation of a feed additive). EFSA received directly from the applicant the technical dossier in support of this application. According to Article 8 of that Regulation, EFSA, after verifying the particulars and documents submitted by the applicant, shall undertake an assessment on the proposals for change made by the applicant. The particulars and documents in support of the application were considered valid by EFSA as of 10 March 2008.
The Scientific Committee on Animal Nutrition (SCAN) has issued three opinions in which monensin sodium was assessed. The first one was issued in 1979 on specific questions about the safety for consumer and the environment of the combined use of the active substance with flavophospholipol (EC, 1979) . The second, issued in 1981, dealt with specific questions about the safety for the consumer and the environment of monensin sodium when used as a coccidiostat in feedingstuff for poultry (EC, 1981) . The third opinion was issued in 1983 and concerned the use of monensin sodium in feedingstuffs for turkeys (EC, 1983) .
The Scientific Panel on Additives and Products or Substances used in Animal Feed (FEEDAP) issued an opinion on the evaluation of the coccidiostat COXIDIN ® (Monensin Sodium) (EFSA, 2005) , following by the opinion on the safety of Coxidin ® (monensin sodium) (EFSA, 2006a) . Than, in the same year, the Panel adopted an opinion on the Maximum Residue Limit for monensin sodium for chickens and turkeys for fattening (EFSA, 2006b) . Finally, in 2007, an opinion on Efficacy of Coxidin ® 25 % (monensin sodium) as a feed additive for turkeys (EFSA, 2007) was adopted.
TERMS OF REFERENCE
According to Article 8 of Regulation (EC) No 1831/2003, EFSA shall determine whether the feed additive complies with the conditions laid down in Article 5. EFSA shall deliver an opinion on the proposal for changing the withdrawal period from three days to one day for the product Coxidin ® , a coccidiostat for chickens and turkeys for fattening with monensin sodium 2008. 7 The second regulation establishes a withdrawal period of three days for the target species and provisional maximum residue limits (MRLs) of 25 μg monensin sodium kg -1 skin/fat, and 8 μg kg -1 liver, kidney and muscle.
The applicant proposes a reduction of the withdrawal period to one day for the abovementioned target species and a modification of the MRLs status from provisional to final. The dossier supporting this application does not contain new studies.
EFSA also received a cross-reference letter from Elanco Animal Health 8 concerning the reduced biological activity of some monensin metabolites and one study on the 14 C-monensin residue decline and metabolism in broiler chickens. These data and study can be shared in the context of setting harmonised MRLs.
Maximum Residue Limits (MRLs)
In its previous opinion on MRLs for monensin sodium for chickens and turkeys (EFSA, 2006b), the FEEDAP Panel proposed 8 μg kg -1 liver, kidney and muscle and 25 μg kg -1 skin/fat as provisional MRLs. Those values were put into force for monensin sodium from Those MRLs are also consistent with the analytical methods available. The most sensitive method showed a LOQ of 2.5 μg kg -1 tissues (Chéneau et al., 2007) . The lowest MRLs were about three times this LOQ, allowing the operational MRL to be at the level of the MRL.
The FEEDAP Panel does not see a possibility for further reduction of those MRLs and/or a change of their provisional character to a definitive status, until an improved analytical method (lower LOQ) is applied and consequently ratios of marker/total residue for the different withdrawal times and tissues could be established.
Toxicological relevance of total monensin residues in tissues

Pharmacological activity of monensin metabolites
Four (Donoho et al., 1982; Davison, 1984) and five monensin metabolites 9 have been identified in chicken excreta and tissues. In chicken trials with labelled monensin only the parent molecule, and possibly the metabolite M2, exceeded 10 % of the total recovered radioactivity in liver. Chemically, the metabolites represent primarily O-demethylated and mono-, di-and tri-hydroxylated derivatives of the parent molecule. Decarboxylated and ketone derivatives are also found. Donoho (1984) summarised the data on the biological properties of the metabolite M1, one of the six O-demethylated metabolites of monensin. It appeared that in a variety of biological systems, i.e. antimicrobial activity against Bacillus subtilis, in vitro anticoccidial activity, cytotoxic activity in an in vitro cell culture system, cardiovascular activity in isolated guinea pig heart preparation and ionophoric activity in isolated rat liver mitochondria preparation, the metabolite exhibited only 5 % of the activity of monensin sodium.
More recent data on the biological activity of the monensin metabolites M1, M2, M5 and M6 (generated by incubation of monensin in the presence of rat liver microsomes, then isolated and purified) were provided and are considered below. 10
Ionophoric properties
Monensin functions as mobile carrier for the metal cations in exchange for protons. This is the basis for establishing the ionophoric properties of monensin (Pressman, 1968 ) and other polyether antibiotics (Wong et al., 1971) . Monensin inhibits by its ionophoric properties ATP hydrolysis in rat liver mitochondria, which can be measured by the reduction of the phosphate release from ATP (Estrada et al., 1968) .
Using a modified assay of Estrada et al., the ionophoric activity of the metabolites M1, M2, M5 and M6 has been measured semi-quantitatively. 10 All metabolites tested appeared to show lower ionophoric activity than the parent compound. However, the data varied widely. Triplicate determinations were available only for the various concentrations of monensin and M1. The results did not show clear dose-dependent effects of monensin and M1. As only single tests were provided for M2, M5, M6, a statistical evaluation could not be performed. M6 appeared to be the most active metabolite. Nevertheless, the authors of the study concluded that the ionophoric activity of the metabolites M1, M2, M5 and M6 could be estimated at < 5 %, < 10 %, < 10 %, and 10 % of that of monensin, respectively.
O-demethylation, decarboxylation and hydroxylation are common metabolic pathways for all polyether ionophoric compounds. Therefore, comparable results on reduced ionophoric activity of metabolites from related polyether antibiotic may support the above findings on monensin. The ionophoric activity of salinomycin metabolites (extracted from the liver of chickens) could be estimated to be approximately 20 % that of salinomycin, when using a 86 Rb radiolabeled binding assay (Dimenna et al., 1989) . Donoho et al. (1982) showed that the percentage of extractable monensin related residues in chicken liver decreased from approximately two-thirds (zero-day withdrawal) to less than onethird after a three-day withdrawal. The authors concluded also that the non-extractable radioactivity likely originates from monensin-derived 14 C that has been extensively metabolised and incorporated into natural tissue components and is therefore not drug-related.
Non-extractable monensin related residues
In a more recent study 11 it could be shown that the non-extractable residues increase with the withdrawal time: in liver of male and female chicken from 37 and 39 % without withdrawal to 51 and 56 % after one-day withdrawal, in kidney from 52 and 40 % to 62 and 51 %, respectively. In the same study it could be shown that about 92 % of a radioactivity in the abdominal fat appeared to be associated to fatty acids.
In a recent opinion, EMEA concluded that 'monensin represented approximately 2 % of the total radioactivity in milk. Approximately 26.5 % of the total radioactivity in milk was determined to be incorporated into endogenous fatty acids.' (EMEA, 2007) .
Taken together, these findings constitute an additional safety factor when assessing consumer safety.
Conclusions
Given the present data on the ionophoric and other biological activities of monensin residues (metabolites), and considering the significant amount of structurally not drug-related (endogenous) residues, the former assessment of the FEEDAP Panel that 'all the metabolites represent a risk which is at most equal to an equivalent quantity of monensin' (EFSA, 2006a) should be re-evaluated.
Considering that
• monensin is only a minor part of the monensin residues,
• selected monensin metabolites show reduced biological activity compared to monensin, and that after a one-day withdrawal period • monensin structurally related metabolites represent only a fraction of the total residues, the FEEDAP Panel concludes that, taking a weight of evidence approach, monensin-derived residues of toxicological relevance probably represent, as a conservative estimate, not more than 50 % of the total residues. This is in agreement with EMEA/CVMP opinion (EMEA, 2007) .
Consumer safety
Re-assessment of human exposure
Based on the most recent total residue study for Coxidin ® (EFSA, 2006b), human exposure after consumption of edible chicken tissues (according to Directive 2001/79/EC) was 0.206 mg day -1 , based on the mean values plus the double standard deviation after a one-day withdrawal. After applying a 50 % reduction of the toxicological relevance of total residues, human exposure would be reduced to 0.103 mg day -1 (57 % of the ADI). In its former opinion on MRLs for monensin in chickens and turkeys (EFSA, 2006b) , the FEEDAP Panel showed that the proposed provisional MRLs for liver, kidney, muscle and skin/fat were in the range of the ADI (101 % of 0.18 mg per person). Table 2 shows the data given in the former opinion and introduces as a new element 'the daily intake of total residues of toxicological relevance (modified DITR)'. Based on this new parameter, consumption of chicken edible tissues would now contribute to 51 % of the ADI. Similar conclusions apply for turkeys for fattening (EFSA, 2006b). 
Withdrawal time
Due to the lack of further data, the ratio marker to total residue used in Table 2 was derived from data at zero-day withdrawal (EFSA, 2006b) . Monensin concentration in edible tissues at zero withdrawal time clearly exceeds the MRLs (Appendix) . Therefore, a zero-day withdrawal time cannot be retained.
But the data obtained after one-day withdrawal (Appendix) were all below the MRLs. Therefore a one-day withdrawal time for Coxidin ® for chickens and turkeys for fattening could be set.
CONCLUSIONS
No new data which would allow proposing a final instead of a provisional MRL for monensin in poultry tissue was provided.
All monensin metabolites tested (M1, M2, M5, M6) appeared to show lower ionophoric activity than the parent compound. These findings confirm the results of earlier studies. Comparable results on reduced ionophoric activity of the metabolites from a related polyether antibiotic support the above findings on monensin.
Non-extractable residues in chicken liver and kidney after a one-day withdrawal period amount to more than 50 % of the total residues. About 90 % of total radioactivity was associated with the abdominal fat in chicken for fattening. Data from dairy cows, taken for comparison because metabolic decarboxylation is a common pathway, indicate that about 25 % of the total residues in milk are attributed to fatty acids. The FEEDAP Panel concludes that a considerable part of the non-extractable residues is not drug-related.
The FEEDAP Panel, following a weight of evidence approach, concludes that monensin derived residues of toxicological relevance probably represent, as a conservative estimate, not more than 50 % of the total residues.
After applying a 50 % reduction of the toxicological relevance of total residue, the human exposure would amount to 0.103 mg day -1 (57 % of the ADI). Based on the MRL values retained, the consumption of chicken edible tissues would contribute to 51 % of the ADI.
Recent marker residue data obtained after one-day withdrawal in chicken for fattening were below the MRLs. Therefore, a one-day withdrawal time for Coxidin ® for chickens and turkeys for fattening could be set.
REMARK
Although a one-day withdrawal period is scientifically justified in terms of consumer safety, the FEEDAP Panel does not consider that the one-day withdrawal is a realistic option under feeding conditions applied to poultry in field.
